German American Bancorp Inc. Has $6.61 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

German American Bancorp Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,714 shares of the company’s stock after selling 4,561 shares during the quarter. German American Bancorp Inc.’s holdings in Johnson & Johnson were worth $6,611,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Principal Financial Group Inc. raised its stake in shares of Johnson & Johnson by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank raised its position in Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after acquiring an additional 202 shares in the last quarter. MML Investors Services LLC lifted its stake in Johnson & Johnson by 8.0% in the third quarter. MML Investors Services LLC now owns 285,256 shares of the company’s stock valued at $46,229,000 after acquiring an additional 21,180 shares during the last quarter. Y Intercept Hong Kong Ltd grew its position in Johnson & Johnson by 1,960.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 46,875 shares of the company’s stock worth $7,597,000 after acquiring an additional 44,600 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its holdings in shares of Johnson & Johnson by 13.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 1,624,842 shares of the company’s stock valued at $263,322,000 after purchasing an additional 192,826 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $150.47 on Tuesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a market capitalization of $362.60 billion, a P/E ratio of 22.63, a P/E/G ratio of 2.56 and a beta of 0.49. The stock has a 50 day moving average of $159.70 and a two-hundred day moving average of $155.66. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the business earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on JNJ. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America boosted their target price on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a report on Wednesday, March 5th. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Finally, Stifel Nicolaus reduced their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.